Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black AfricansReport as inadecuate




Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans - Download this document for free, or read online. Document in PDF available to download.

Advances in HematologyVolume 2013 2013, Article ID 901589, 5 pages

Clinical Study

Department of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d-Ivoire

Department of Biological Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d-Ivoire

Received 31 March 2013; Revised 13 May 2013; Accepted 14 May 2013

Academic Editor: Giuseppe G. Saglio

Copyright © 2013 Tolo Diebkilé Aïssata et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Imatinib mesylate provides good results in the treatment of CML in general. But what about the results of this treatment in CML associated with additional cytogenetic abnormalities at diagnosis among black Africans?For this, we retrospectively studied 27 cases of CML associated with additional cytogenetic abnormalities, diagnosed in the department of clinical hematology of the University Hospital of Yopougon in Côte d-Ivoire, from May 2005 to October 2011. The age of patients ranged from 13 to 68 years, with a mean age of 38 years and a sex ratio of 2. Patients were severely symptomatic with a high Sokal score of 67%. CML in chronic phase accounted for 67%. The prevalence of additional cytogenetic abnormalities was 29.7%. There were variants of the Philadelphia chromosome 18.5%, trisomy 8 14.8%, complex cytogenetic abnormalities 18.5%, second Philadelphia chromosome 14.8%, and minor cytogenetic abnormalities 44.4%. Complete hematologic remission was achieved in 59%, with 52% of major cytogenetic remission. The outcome was fatal in 37% of patients. Death was related in 40% to hematologic toxicity and in 30% to acutisation. The median survival was 40 months.





Author: Tolo Diebkilé Aïssata, Duni Sawadogo, Clotaire Nanho, Boidy Kouakou, N-dogomo Meité, N-Dhatz Emeuraude, Ayémou Roméo, 

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents